PD-L1 protein expression on immune cells, tumor mutation burden (TMB), and the TGFβ pathway have been shown to correlate with the clinical outcome of immune checkpoint inhibitor (ICI) therapy for advanced urothelial cancer [11]. Here, CD274 is linked to neoplasm.